Company Overview and News
As bond yields and the price of crude oil inch higher, inflation will sooner or later become an issue for income based investors. Dividend stocks which have not been growing their dividend at a reasonable clip will come under pressure as there will be more options open to income derived investors. One option is Inter Pipeline Ltd. (OTCPK:IPPLF) which pays out almost a 7%+ dividend. Obviously, with these kinds of yields, doing the necessary due diligence is critical before attempting to scale into any sort of long position.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CVE IMO CNQ CVE IMO IPPLF IPL SU SU
On April 24, W. R. Grace (GRA) announced that it would be licensing its UNIPOL PP Process Technology to Inter Pipeline to be used in its Heartland Petrochemical complex in Alberta, Canada. The pipeline is expected to be in service by 2021. W.R. Grace did not specify the financial aspects of the deal, its second so far in 2018.
After back-to-back 3% weekly gains, MLPs traded up slightly for a third straight week, slightly ahead of the S&P 500. As discussed last week, MLPs haven't had 3% gains 3 weeks in a row ever, so this week's pause is not a surprise, especially with flat broad market and oil prices.
TRP SXCP IPPLF IPL AR
March 15 - April 10, Fredrik Arnold "followers" mentioned 37 equities in their comments and suggestions. Some lamented bad news so bad news stocks mixed-in with their favorites.
AIY AINV HMLP UNIT CTL STX ORC IPL NAP EQM CYS.PRA GM.WS.A CJR.B CYS.PRB GM.WS.B TWO GM.WS.C GM TWO.PRA IPPLF TWO.PRB TWO.PRC AIB TRTN CYS CJREF GMLP QCOM GM.WSB HMLP.PRA PBA
Midstream posted another strong week overall, and MLPs led the way again, up 3.5% for a second straight week. The midstream rally couldn't be stopped by another 13 basis points added to the U.S. 10-year interest rate. The rally even withstood a Tweet from President Trump about how oil prices are too high. As good as the overall week turned out, the rally was confined to just 2 days, with negative returns in the other 3, just like last week.
PBF KMI PBFX EPD PBA IPPLF IPL
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to TSX:IPL / Inter Pipeline Ltd on message board site Silicon Investor.